Avalo Therapeutics increases ATM offering capacity to $50M from $9M

Avalo Therapeutics, Inc.

Amended Sales Agreement with Oppenheimer ups aggregate offering to $50,000,000.
As of Aug 4, 2023, had sold ~$8.3M of common stock under prior $9.03M limit.
Remaining capacity under amended agreement is approximately $41.7M.
Shares sold via 'at the market' offering under existing registration statement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Avalo Therapeutics, Inc. amended Amendment No. 1 to the Sales Agreement with Oppenheimer & Co. Inc. valued at up to $50,000,000 (effective 2023-08-07).

Action: amendment
Agreement: atm program
Counterparty: Oppenheimer & Co. Inc.
Value: up to $50,000,000
Effective: 2023-08-07

Exact text from the filing

On August 7, 2023, the Company and Oppenheimer entered into Amendment No. 1 to the Sales Agreement (the “Amendment”, and together with the Sales Agreement, the “Amended Sales Agreement”) to provide for an increase in the aggregate offering amount under the Sales Agreement, such that as of August 7, 2023 under the Amended Sales Agreement, the Company may offer and sell additional shares of common stock having an aggregate offering price of up to $50,000,000

View on SEC.gov

622 material agreements filed in the last 30 days. Browse all material agreements →

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-027842

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.